Encouraging Antibiotic Innovation

Return to main article:

One of the chief obstacles to finding new antibiotics is that many pharmaceutical companies have stopped looking. According to a report by the Infectious Diseases Society of America, just five major firms were engaged in antibiotic discovery in 2009; others, discouraged by economic and regulatory challenges, have left the field. Even worse, the report warned, “We remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs.”

The economics of antibiotics pose a major barrier to pharmaceutical investment. Antibiotics are no cheaper to develop than other drugs, but they bring in less revenue: unlike treatments for chronic conditions like asthma or high cholesterol, antibiotics are given in courses that typically last only a few weeks. Moreover, because resistant infections are on the rise, newly approved antibiotics are held in reserve, to be used only after more common treatments fail. To encourage antibiotic development, Congress passed an act in 2012 that granted companies an extra five-year exclusive-marketing period for new drugs that combat infectious diseases, and public-private partnerships are beginning to subsidize the cost of research and clinical trials.

Such clinical trials are a formidable second hurdle: the drug-approval process traditionally requires large, costly trials with many patients. For companies developing treatments for drug-resistant pathogens, says John Rex, head of infection development at AstraZeneca, “That means the epidemic has to have already occurred.” The European Union recently created a new, streamlined pathway for antibiotic approval; the U.S. Food and Drug Administration is considering similar guidelines. The pathway would permit smaller, more rapid trials for drugs that target resistant pathogens; they are similar in concept to guidelines for “orphan drugs” that treat rare diseases. Drugs approved under this pathway would carry a more provisional usage label, advocating their prescription only in well-defined cases in which other options have been exhausted. Such drugs might be considerably more expensive as well, reflecting their medical value. “Antibiotics save your life,” says Rex. “And on average, they give you back many years of life”—but they are currently among the cheapest drugs. When accounting for the years of life saved, Rex and colleagues have argued that a course of novel antibiotics given to treat an otherwise resistant infection might rationally cost $30,000. 

Together, the new policies aim to draw companies back into antibiotic development, leading to future innovation. “What I really want to see is a diverse, vibrant drug pipeline,” says Rex. “We’re not quite to that yet, but we’ve laid the groundwork.”

Related topics

You might also like

In Sermon, Garber Urges Harvard Community to ‘Defend and Protect’ Institutions

Harvard’s president uses traditional Memorial Church address to encourage divergent views.

A New Narrative of Civil Rights

Political philosopher Brandon Terry’s vision of racial progress

This Astronomer Is Sounding a Warning On 'Space Junk'

As debris accumulates in low Earth orbit, the danger of destructive collisions continues to rise.

Most popular

What Trump Means for John Roberts’s Legacy

Executive power is on the docket at the Supreme Court.

How Maga Went Mainstream at Harvard

Trump, TikTok, and the pandemic are reshaping Gen Z politics.

Explore More From Current Issue

Two people moving large abstract painting with blue V-shaped design in museum courtyard.

A Harvard Art Museums Painting Gets a Bath

Water and sunlight help restore a modern American classic.

Catherine Zipf smiling, wearing striped shirt and dark sweater outdoors.

Preserving the History of Jim Crow Era Safe Havens

Architectural historian Catherine Zipf is building a database of Green Book sites.  

Whimsical illustration of students rushing through ornate campus gate from bus marked “Welcome New Students.”

Highlights from Harvard’s Past

The Medical School goes coed, University poet wins Nobel Prize.